It gave good results in phase 1 and 2 (I thought phase 2 was still ongoig)..but here it is!
This Phase 3 clinical trial is investigating xaluritamig, an experimental drug, for metastatic castration-resistant prostate cancer (mCRPC). The study compares xaluritamig to standard treatments, such as cabazitaxel or a second androgen receptor-directed therapy (ARDT).
The trial is enrolling adult patients with mCRPC who meet specific criteria, including prior treatment with at least one ARDT and one taxane therapy. Participants are randomly assigned to receive either xaluritamig or a standard treatment. The study involves multiple visits and procedures over an extended period.
The trial should start enrolling in January 2025 in various locations.
New Car-T therapy announces initial results, how exercise helps in the fight against cancer, FDA approves EZRA AI for faster PC diagnosis